SEC Filing Summary
Entity identification: The request identifies Climb Bio, Inc., but the supplied Form 10-Q is for Eliem Therapeutics, Inc. (Nasdaq: ELYM). This summary reflects the filing provided and should not be attributed to Climb Bio without verification.
Business context and reporting period
Eliem is a clinical-stage biotechnology company developing therapies for neuronal excitability disorders. The filing covers the quarter and nine months ended September 30, 2021; financial statements are unaudited. The company had no approved products and generated no product revenue.
Lead programs: ETX-810, in two Phase 2a trials for pain indications, with topline results expected in the first half of 2022; and ETX-155, in clinical development for depression and epilepsy. The company expected to begin dosing in an epilepsy Phase 1b trial by year-end 2021, and to start Phase 2a trials in major depressive disorder and perimenopausal depression in early 2022, subject to regulatory approval.
Key financial metrics
Amounts below are in U.S. dollars; financial statement amounts are in millions unless otherwise stated.
| Metric | Three months ended September 30, 2021 | Nine months ended September 30, 2021 | Comparable 2020 period |
|---|---|---|---|
| Revenue | None reported | None reported | None reported |
| Research and development expense, including related-party expense | $5.99 million | $16.44 million | $1.95 million; $4.93 million |
| General and administrative expense | $3.39 million | $8.53 million | $0.31 million; $0.89 million |
| Total operating expenses | $9.38 million | $24.97 million | $2.26 million; $5.82 million |
| Net loss | $9.62 million | $36.94 million | $2.26 million; $5.81 million |
| Net loss per common share, basic and diluted | $0.70 | $5.49 | $1.46; $3.85 |
| Net cash used in operating activities | $28.19 million for nine months | $8.47 million for nine months |
The nine-month 2021 net loss included an $11.72 million noncash charge from remeasurement of a preferred-stock tranche liability. There is no meaningful product gross margin because the company had no product sales.
At September 30, 2021, cash and cash equivalents were $62.82 million and marketable securities were $106.82 million, totaling $169.64 million. Total assets were $182.25 million, current liabilities and total liabilities were $5.59 million, and stockholders’ equity was $176.66 million. No debt balance was reported. Accumulated deficit was $65.07 million.
Cash flows for the first nine months of 2021 included $106.92 million used to purchase marketable securities and $177.19 million provided by financing, principally preferred-stock financings and the IPO. Cash and cash equivalents increased by $42.33 million to $62.82 million.
Material changes versus prior comparable periods
- Operating expenses and losses rose substantially as the company advanced clinical and preclinical programs, expanded staffing, and incurred public-company costs. Third-quarter R&D expense including related-party expense increased to $5.99 million from $1.95 million; G&A increased to $3.39 million from $0.31 million.
- Nine-month 2021 net loss increased to $36.94 million from $5.81 million. The increase includes the $11.72 million tranche-liability fair-value charge; excluding this unusual noncash charge, net loss was still higher year over year.
- The company raised $83.1 million net in its August 2021 IPO and received $93.9 million net from 2021 preferred-stock issuances. At the IPO, all preferred shares converted into 15.35 million common shares. The IPO issued 7.36 million shares at $12.50 per share.
- Marketable securities rose from none at December 31, 2020 to $106.82 million at September 30, 2021. Prepaid expenses and other current assets increased to $12.61 million, including $6.94 million in recoverable R&D tax credits.
Outlook, commentary, risks and unusual items
- Management’s operating-plan estimate was that cash, cash equivalents and marketable securities would fund operating expenses and capital expenditures through late 2023. The liquidity note separately states resources were sufficient for at least twelve months from the financial-statement issuance date. Management said substantial additional funding will ultimately be needed; estimates depend on assumptions and cash could be used sooner.
- Management expected R&D and G&A expenses and operating losses to increase as clinical trials, staffing, regulatory work and public-company obligations expand. The company warned it may need additional equity, debt, collaborations or other financing, with no assurance funding will be available on acceptable terms.
- A Phase 1 repeat-dose ETX-155 study in 20 healthy subjects was reported as generally well tolerated, with no severe or serious adverse events or discontinuations. The filing notes these findings are early-stage and do not establish efficacy or predict later trial outcomes.
- COVID-19 had not materially affected operations or financing to date, according to management, but could disrupt enrollment, trial sites, vendors, manufacturing and timelines.
- Disclosure controls were deemed ineffective as of September 30, 2021 because of material weaknesses in the control environment, accounting policies and procedures, and IT general controls. Management said the weaknesses had not been remediated; remediation efforts included hiring accounting personnel and consultants and implementing financial systems and controls. The weaknesses had not resulted in a reported financial-statement misstatement.
- The filing reported no material legal proceedings and no off-balance-sheet arrangements. UK operating leases carried future minimum payments of $0.6 million through dates ending June 30, 2023.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is Eliem Therapeutics, Inc., not Climb Bio, Inc.
- Track ETX-810 and ETX-155 trial enrollment, regulatory status, topline timing and final data against the stated expectations.
- Reconcile the runway disclosures—at least twelve months from issuance versus through late 2023—and monitor spending and financing needs.
- Assess progress in remediating the disclosed material weaknesses and whether controls are tested and operating effectively.
- Review the noncash preferred-stock tranche charge and IPO/preferred-stock conversion when comparing reported losses, per-share results and share counts.